Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca reports positive trial findings for heart treatment

AstraZeneca reports positive trial findings for heart treatment

18th March 2010

AstraZeneca has published clinical study data which underlines the efficacy of its oral antiplatelet drug Brilique in treating acute coronary syndromes.

The performance of the pharmaceutical company’s treatment was compared against the alternative option clopidogrel among 1,261 patients tested seven days prior to having heart bypass surgery.

It was found that those using Brilique experienced a 51 per cent reduction in mortality rates compared to the clopidogrel group, which means that the study accomplished its primary endpoint.

In addition, it was found that rates of severe bleeding relating to the coronary artery bypass graft surgery were not significantly different between the two patient groups.

Brilique remains the subject of regulatory review in both Europe and the US, where it is marketed under the name Brilinta.

Earlier this month, the company acquired the rights to license and market a range of generic drugs from Torrent Pharmaceuticals, allowing it to expand its activities in the sector.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.